Home / Science / New B12 Therapy Targets Aggressive Brain Cancer
New B12 Therapy Targets Aggressive Brain Cancer
29 Jun
Summary
- Modified vitamin B12 crosses blood-brain barrier to target tumors.
- Compound shows promise in combination with existing treatments.
- Further research needed before clinical application can be considered.
A recent study published in Oncoscience has investigated nitrosylcobalamin (NO-Cbl), a modified version of vitamin B12, as a novel therapeutic strategy for glioblastoma. This aggressive brain cancer has a notoriously poor prognosis due to its resistance to current treatments and the challenge of the blood-brain barrier.
The research focused on whether NO-Cbl could penetrate this protective barrier and specifically target glioblastoma tumors. Experiments confirmed that NO-Cbl successfully crossed the blood-brain barrier in animal models and remained active in tumor tissue for extended periods, suggesting selective accumulation.
Furthermore, laboratory tests revealed that NO-Cbl significantly enhanced the efficacy of established glioblastoma therapies, including temozolomide and TRAIL. The compound demonstrated synergistic activity, leading to greater suppression of tumor cell growth than treatments used individually.
While these pilot study results are encouraging, the authors stress that extensive further research is necessary. Future investigations will aim to optimize dosing, explore underlying mechanisms, and validate these findings in additional central nervous system tumor models before clinical application can be pursued.
